US Health and Human Services' Thompson set for talks with AdvaMed:
This article was originally published in Clinica
Executive Summary
US Health and Human Services Secretary Tommy Thompson will demonstrate his continued interest in the medical device industry this week when he meets with AdvaMed's board of directors on June 20. Mr Thompson has been an outspoken advocate for medical device user fees and his drive to unite his sprawling sinecure into one department is already fostering greater co-operation within its various powerhouse health agencies. At AdvaMed's recent Device Submission Workshop, there was repeated talk about the US FDA collaborating with the National Institutes of Health, with Medicare administrators and with the Centers for Disease Control and Prevention.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.